Aim. This article reviews current opinions on epidemiology, pathogenesis, diagnosis and treatment of tardive dyskinesia.
Review. The incidence of tardive dyskinesia is expected to decline with increasing use of atypical antipsychotic drugs, the risk in susceptible patients, the continued use of older conventional antipsychotics, and the legacy of thousands of patients who previously acquired dyskinesias, underscore the relevance of this potentially irreversible adverse drug reaction. Considerable evidence has accumulated concerning the epidemiology, clinical presentation, pathogenesis and management of tardive dyskinesia.
Conclusions. Belter understanding of the condition is important not only for clinical practice, but also in elucidating the interaction between antipsychotic drugs and dyskinetic vulnerability associated with schizophrenia and ageing.